About FDA

Division of Prescription Drugs

Director: Kalah Auchincloss, J.D., MPH

Team Leader, Compounding Operations Team: Pamela Lee, J.D., P.A.

Team Leader, Compounding Policy Team: Marissa Brykman, J.D. (acting)

Team Leader, Regulatory Status and Labeling Team: Kim Simmons, J.D., R.Ph.

Team Leader, Marketed Unapproved Drugs Enforcement Team: Barbara Wise, Ph.D., RN, CPNP 

Project Management Officer: Kelisha Turner, MS, CMQ/OE 

The Division of Prescription Drugs is responsible for directing inspections and investigations and recommending, directing and/or coordinating case development and compliance actions relating to prescription drug products; providing enforcement and litigation support and guidance for prescription drug products; providing guidance relating to drug establishment registration and drug product listing regulations and regulatory status of domestic and imported drug products marketed in the U.S. 

DPD uses risk-based assessments to identify and prioritize unapproved prescription drugs for regulatory action and develops compliance strategies to address violations; and reviews and develops legislative proposals and implementing regulations, policy and guidance documents, enforcement strategies, and outreach activities related to prescription drugs. 

For additional information, please visit:

Page Last Updated: 12/11/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English